Physician profile
Erwin Lerebours
NPI 1699722587
$841.86
in general payments reported to CMS, 2019-2025
9 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.00 · 2023: $543 · 2024: $103 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.59 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $301.90 | 2023-2024 | Myfembree |
| Davol INC. | $154.51 | 2023 | |
| Phathom Pharmaceuticals, INC. | $124.82 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $101.53 | 2023-2024 | Acessa Provu System, Myosure Tissue Removal Device |
| Organon LLC | $66.74 | 2022-2024 | Nexplanon |
| Shield Therapeutics INC | $25.30 | 2025 | |
| Viiv Healthcare Company | $23.31 | 2024 | Apretude |
| Myriad Women'S Health, INC. | $23.00 | 2023 | Myrisk |
| Merck Sharp & Dohme LLC | $20.75 | 2025 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Lerebours listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.